Clinical Trials in Guangxi, China

4 recruiting

Showing 110 of 10 trials

Recruiting
Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled253 locationsNCT05899608
Recruiting
Phase 1Phase 2

Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer

Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.105 enrolled30 locationsNCT07367516
Recruiting
Phase 1

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Not Applicable

SV With TTPEE Measurement Predicts Upper Airway Patency in Prolonged Tracheostomy Patients

Tracheostomy
Capital Medical University300 enrolled5 locationsNCT07107243
Recruiting
Phase 1Phase 2

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Advanced Cancer
Suzhou Transcenta Therapeutics Co., Ltd.320 enrolled40 locationsNCT04495296
Recruiting

A Prognostic Model for Drug-induced Liver Injury in China

Drug-Induced Liver Injury
Beijing Friendship Hospital3,000 enrolled13 locationsNCT05060289
Recruiting
Phase 1

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

Thalassemia
Shenzhen Hemogen8 enrolled3 locationsNCT06655662
Recruiting
Not Applicable

α-ketoglutarate in Patients With Hypertension

Hypertension
Jun Tao30 enrolled1 locationNCT06445244
Recruiting

Chinese Psoriasis Real World Evidence Research

Psoriasis
Second Affiliated Hospital, School of Medicine, Zhejiang University10,000 enrolled29 locationsNCT04465838
Recruiting
Phase 3

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891